Bannister, Wendy P.
Mayo Clinic
Phastar, London, United Kingdom;
Citations 1
EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD.
Ruddy, Kathryn J. , Li, Wei , Goessl, Carsten, Degboe, Arnold, Hettle, Robert , Robson, Mark E. , Im, Seock‐Ah , Senkus, Elżbieta , Xu, Binghe , Domchek, Susan M. , Masuda, Norikazu , Tung, Nadine , Armstrong, Anne Caroline , Bannister, Wendy P. , Conte, PierFranco
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1045-1045
